Core Laboratories N.V. (CLB)

Core Laboratories (CLB) reported earnings 30 days ago. What's next for the stock?

CLB struggles with a 4.4% revenue decline, low ROIC in the first quarter of 2025, minimal dividends and vulnerability to oil price volatility and geopolitical instability.

AMTB, CLB and EXPI have been added to the Zacks Rank #5 (Strong Sell) List on May 14, 2025.

CLB's first-quarter earnings miss estimates due to the underperformance of the Reservoir Description segment.

Core Laboratories Inc. (NYSE:CLB ) Q1 2025 Earnings Conference Call April 24, 2025 8:30 AM ET Company Participants Larry Bruno - Chairman and Chief Executive Officer Gwen Gresham - Senior Vice Preside...

AMPY, CARS and CLB have been added to the Zacks Rank #5 (Strong Sell) List on April 24, 2025.

Core Laboratories (CLB) came out with quarterly earnings of $0.14 per share, missing the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.19 per share a year ago.

CLB's first-quarter revenues are likely to have declined from the year-ago period's level. However, cost reductions are expected to have provided modest relief.

Core Laboratories (CLB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CLB faces declining revenues, weak margins, geopolitical disruptions and inventory issues, with low dividend yield and overvaluation increasing investor caution.